Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. But the pair’s success leaves room for improvement for future contenders.

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

The TellDx CTC iChip platform enables high-efficiency isolation of intact circulating tumor cells without reliance on cell size or epithelial markers. This unbiased approach is particularly well ...

Dr. Zhonglin Hao says small cell lung cancer usually occurs in smokers and often recurs after treatments that are currently available. (University of Kentucky photo) If you smoke and want to quit, ...

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...

The anti-cancer drug durvalumab used in immunotherapy delivers a 66-month survival breakthrough for lung cancer patients, ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Cancer cells with a cell nucleus that is easily deformed are more sensitive to drugs that damage DNA. These are the findings of a new study by researchers at Linköping University in Sweden. The ...